Drug Trial Radar · NCT06427941
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
630
Planned (sponsor's estimate)
Start
Jul 23, 2024
Primary completion
Mar 31, 2027
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- May 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without bevacizumab, in adults with advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors, non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC). The study will also determine the recommended Phase 2 dose (RP2D) of BGB-B2033 when given alone or in combination with tislelizumab and bevacizumab. The main questions it aims to answer are: * Is BGB-B2033 safe and tolerable when given alone or in combination with tislelizumab, with or without bevacizumab? * How does the body process BGB-B2033, and what are its effects on the body? * Does BGB-B2033 show preliminary antitumor activity in participants with advanced or metastatic cancer? Researchers will evaluate different doses and treatment combinations to determine the safest and most appropriate dose of BGB-B2033 for further study. Participants will: * Receive BGB-B2033 by intravenous infusion, either alone or in combination with tislelizumab, with or without bevacizumab. * Have regular assessments to monitor safety, side effects, how their body processes and responds to BGB-B2033, and whether their cancer responds to treatment.
Conditions
- Metastatic Hepatocellular Carcinoma
- Local Advanced Hepatocellular Carcinoma
- Alpha-fetoprotein (AFP)-Producing Gastric Cancer
- Extragonadal Yolk Sac Tumors
- Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Interventions
BGB-B2033Drug
Administered by intravenous infusion
TislelizumabDrug
Administered by intravenous infusion
BevacizumabDrug
Administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 2 years
- Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033Time frame: Up to approximately 2 years
- Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033Time frame: Up to approximately 2 years
- Parts C, D, and E: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)Time frame: Up to approximately 2 years
Locations
51 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham Hospital
Birmingham, Alabama · Recruiting
City of Hope Phoenix Cancer Center
Goodyear, Arizona · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
City of Hope Chicago Cancer Center
Zion, Illinois · Recruiting
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York · Recruiting
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, Pennsylvania · Recruiting
Scri Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas · Recruiting
Fundacao Pio Xii Hospital de Amor de Barretos
Barretos, Brazil · Recruiting
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
Porto Alegre, Brazil · Recruiting
Hospital Da Bahia
Salvador, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, Brazil · Recruiting
Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira
São Paulo, Brazil · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital Wuxiang Branch
Nanning, Guangxi, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch
Nanchang, Jiangxi, China · Recruiting
Sichuan Cancer Hospital and Institute
Chengdu, Sichuan, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Lishui Central Hospital
Lishui, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Hopital Beaujon
Clichy, France · Recruiting
Centre Hospitalier Universitaire Nantes Hotel Dieu
Nantes, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Irccs Istituto Nazionale Tumori Fondazione Pascale
Naples, Italy · Recruiting
Iov Istituto Oncologico Veneto Irccs
Padova, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy · Recruiting
Irccs Humanitas Research Hospital
Rozzano, Italy · Recruiting
Kindai University Hospital
Sakai, Osaka, Japan · Recruiting
Tokyo Metropolitan Komagome Hospital
Bunkyoku, Tokyo, Japan · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.